Immunotherapy in head and neck squamous cell carcinoma

"Immunotherapy in head and neck squamous cell carcinoma.Immune checkpoint inhibitors became recently the standard of care for recurrent and/or metastatic head and neck squamous cell carcinoma not amenable to surgery and/or radiotherapy. Nivolumab as single agent is approved regardless of PD-L1 expression for recurrent and/or metastatic patients following progression within 6 months of platinum therapy administered either in the first line recurrent setting, or concomitantly with radiotherapy. Pembrolizumab in combination with platinum and 5-FU and pembrolizumab a single agent are two approved regimens in the first line recurrent and/or metastatic setting, provided: PD-L1 expression on tumour cells and/or inflammatory cells, and lack of disease progression within 6 months of platinum therapy given concomitantly with radiotherapy."